WO2011143262A3 - Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses - Google Patents

Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses Download PDF

Info

Publication number
WO2011143262A3
WO2011143262A3 PCT/US2011/035982 US2011035982W WO2011143262A3 WO 2011143262 A3 WO2011143262 A3 WO 2011143262A3 US 2011035982 W US2011035982 W US 2011035982W WO 2011143262 A3 WO2011143262 A3 WO 2011143262A3
Authority
WO
WIPO (PCT)
Prior art keywords
influenza
oseltamivir
viruses
methods
neuraminidase inhibitors
Prior art date
Application number
PCT/US2011/035982
Other languages
French (fr)
Other versions
WO2011143262A2 (en
Inventor
Chi-Huey Wong
Jim-Min Fang
Yih-Shyun Cheng
Jiun-Jie Shie
Original Assignee
Sinica, Academia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13/697,794 priority Critical patent/US9403855B2/en
Application filed by Sinica, Academia filed Critical Sinica, Academia
Priority to CA2835489A priority patent/CA2835489C/en
Priority to DK11731548.1T priority patent/DK2568976T3/en
Priority to AU2011250970A priority patent/AU2011250970B2/en
Priority to KR1020177014263A priority patent/KR101915647B1/en
Priority to EP11731548.1A priority patent/EP2568976B1/en
Priority to KR1020127032244A priority patent/KR101745386B1/en
Priority to CN201180034218.3A priority patent/CN103068378B/en
Priority to JP2013510261A priority patent/JP5947289B2/en
Priority to EP15181446.4A priority patent/EP2975409B1/en
Publication of WO2011143262A2 publication Critical patent/WO2011143262A2/en
Publication of WO2011143262A3 publication Critical patent/WO2011143262A3/en
Priority to US15/210,565 priority patent/US9874562B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Abstract

Methods and compositions for detection of drug resistant pathogens and treatment against infections thereof are provided. Methods for detection of oseltamivir-resistant influenza viruses by competitive binding assays utilizing non- oseltamivir influenza virus neuraminidase inhibitors and oseltamivir carboxylate are provided. Influenza virus neuraminidase inhibitors coupled to sensors and useful for employment in the methods of the invention are disclosed. Novel phosphonate compounds active as neuraminidase inhibitors against wild-type and oseltamivir-resistant influenza strains of H1N1, H5N1 and H3N2 viruses are disclosed. An enantioselective synthetic route to preparation of these phosphonate compounds via sialic acid is provided.
PCT/US2011/035982 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses WO2011143262A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP11731548.1A EP2568976B1 (en) 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
CA2835489A CA2835489C (en) 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
DK11731548.1T DK2568976T3 (en) 2010-05-10 2011-05-10 Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
AU2011250970A AU2011250970B2 (en) 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
KR1020177014263A KR101915647B1 (en) 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US13/697,794 US9403855B2 (en) 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
KR1020127032244A KR101745386B1 (en) 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
EP15181446.4A EP2975409B1 (en) 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
JP2013510261A JP5947289B2 (en) 2010-05-10 2011-05-10 Determination of the susceptibility of zanamivir phosphonate congeners with anti-influenza activity and influenza virus to oseltamivir
CN201180034218.3A CN103068378B (en) 2010-05-10 2011-05-10 Zanamivir phosphonate ester congener with anti-influenza activity and preparation method thereof
US15/210,565 US9874562B2 (en) 2010-05-10 2016-07-14 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33313710P 2010-05-10 2010-05-10
US61/333,137 2010-05-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/697,794 A-371-Of-International US9403855B2 (en) 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US15/210,565 Division US9874562B2 (en) 2010-05-10 2016-07-14 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses

Publications (2)

Publication Number Publication Date
WO2011143262A2 WO2011143262A2 (en) 2011-11-17
WO2011143262A3 true WO2011143262A3 (en) 2012-03-01

Family

ID=44583353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/035982 WO2011143262A2 (en) 2010-05-10 2011-05-10 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses

Country Status (9)

Country Link
US (2) US9403855B2 (en)
EP (2) EP2975409B1 (en)
JP (1) JP5947289B2 (en)
KR (2) KR101915647B1 (en)
CN (2) CN103068378B (en)
AU (1) AU2011250970B2 (en)
CA (1) CA2835489C (en)
DK (2) DK2568976T3 (en)
WO (1) WO2011143262A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5986745B2 (en) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Glycan arrays on PTFE-like aluminum-coated glass slides and related methods
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US10130714B2 (en) * 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9258549B2 (en) * 2012-05-14 2016-02-09 Intuitive Surgical Operations, Inc. Single-chip sensor multi-function imaging
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9487816B2 (en) 2013-03-15 2016-11-08 University Of Cincinnati Methods of detecting influenza virus
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
CN105682666B (en) 2013-09-06 2021-06-01 中央研究院 Activation of human iNKT cells using glycolipids
JP6453050B2 (en) * 2013-11-15 2019-01-16 国立大学法人富山大学 2-deoxy-2,3-didehydrosialic acid derivative and method for producing the same
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI687428B (en) 2014-03-27 2020-03-11 中央研究院 Reactive labelling compounds and uses thereof
CN105017193B (en) * 2014-04-22 2018-11-09 江苏先声药业有限公司 A kind of preparation method of zanamivir impurity
EP3149161B1 (en) 2014-05-27 2021-07-28 Academia Sinica Fucosidase from bacteroides and methods using the same
CN106573971A (en) 2014-05-27 2017-04-19 中央研究院 Anti-CD20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
TWI732738B (en) 2014-05-28 2021-07-11 中央研究院 Anti-tnf-alpha glycoantibodies and uses thereof
CZ305660B6 (en) * 2014-06-27 2016-01-27 Univerzita Karlova V Praze Oxytocin analogs
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
KR101575747B1 (en) * 2015-04-06 2015-12-21 한국생명공학연구원 Antiviral agent-sensitive/resistant virus detection system
WO2017007204A1 (en) * 2015-07-03 2017-01-12 한국생명공학연구원 Antiviral-agent-resistant virus detection system
KR101788454B1 (en) 2015-07-03 2017-10-19 한국생명공학연구원 Antiviral agent-resistant virus detection system
WO2017011686A1 (en) * 2015-07-14 2017-01-19 University Of Iowa Research Foundation Fluorescent prodrugs
PL227790B1 (en) 2015-08-13 2018-01-31 Slaski Univ Medyczny W Katowicach Phosphonates of acetylene derivatives of betulin with antitumour effects, method for producing them and applications
TW201808978A (en) 2016-03-08 2018-03-16 中央研究院 Methods for modular synthesis of N-glycans and arrays thereof
JP7213549B2 (en) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド Antibodies, Binding Fragments, and Methods of Use
CN107827830B (en) * 2017-11-13 2021-08-06 山东省农业科学院家禽研究所 Oseltamivir derivative and preparation method and application thereof
PL237998B1 (en) 2018-05-28 2021-06-28 Narodowy Inst Lekow Phosphonic derivatives of 3-carboxyacylbetulinic acid, method for obtaining them and their application
WO2020023323A1 (en) * 2018-07-26 2020-01-30 Purdue Research Foundation Small molecule ligand-targeted drug conjugates for anti-influenza chemotherapy and immunotherapy
CR20210166A (en) 2018-09-06 2021-07-27 Cidara Therapeutics Inc Compositions and methods for the treatment of viral infections
TW202122117A (en) 2019-09-06 2021-06-16 美商席達拉醫療有限公司 Compositions and methods for the treatment of viral infections
CN111233962B (en) * 2020-03-12 2021-06-04 中国科学院微生物研究所 Influenza virus neuraminidase inhibitor and preparation method and application thereof
CN111533754B (en) * 2020-04-20 2021-05-11 上海应用技术大学 Benzocoumarin chalcone neuraminidase inhibitor and preparation method and application thereof
WO2022241262A2 (en) * 2021-05-14 2022-11-17 Purdue Research Foundation Small molecule-based bi-specific immune cell tethers and their use in the treatment of enveloped virus infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029888A2 (en) * 2007-08-31 2009-03-05 Chi-Huey Wong Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity
EP2123271A1 (en) * 2007-03-07 2009-11-25 Daiichi Sankyo Company, Limited Drug for treatment of influenza

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
US5238843A (en) 1989-10-27 1993-08-24 Genencor International, Inc. Method for cleaning a surface on which is bound a glycoside-containing substance
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
AP249A (en) * 1990-04-24 1993-03-17 Biota Scient Management Pty Ltd Anti-viral compounds.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06500011A (en) 1990-06-29 1994-01-06 ラージ　スケール　バイオロジー　コーポレイション Production of melanin by transformed microorganisms
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992006691A1 (en) 1990-10-19 1992-04-30 Biota Scientific Management Pty. Ltd. Anti-viral compounds that bind the active site of influenza neuramidase and display in vivo activity against orthomyxovirus and paramyxovirus
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586515B1 (en) 1991-04-30 1997-09-17 Eukarion, Inc. Cationized antibodies against intracellular proteins
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
DK0605522T3 (en) 1991-09-23 2000-01-17 Medical Res Council Process for producing humanized antibodies
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69334095T2 (en) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Method for intracellular binding of targeted molecules
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
ATE149570T1 (en) 1992-08-17 1997-03-15 Genentech Inc BISPECIFIC IMMUNOADHESINS
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE306930T1 (en) 1994-08-12 2005-11-15 Immunomedics Inc IMMUNE CONJUGATES AND HUMAN ANTIBODIES SPECIFIC FOR B-CELL LYMPHOMA AND LEUKEMIA CELLS
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ES2304786T3 (en) 1995-04-27 2008-10-16 Amgen Fremont Inc. ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
ES2197330T3 (en) 1996-03-01 2004-01-01 Biota Scientific Management Pty. Ltd. METHOD FOR DETECTING THE FLU VIRUS AND COMPOUNDS TO USE IN THE.
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
TW555562B (en) 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ATE321066T1 (en) 1998-05-06 2006-04-15 Genentech Inc ANTI-HER2 ANTIBODY COMPOSITION
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
FR2783523B1 (en) 1998-09-21 2006-01-20 Goemar Lab Sa FUCO-OLIGOSACCHARIDES, ENZYME FOR THEIR PREPARATION FROM FUCANES, ENZYME-PRODUCING BACTERIA AND APPLICATIONS OF FUCO-OLIGOSACCHARIDES FOR PLANT PROTECTION
US7090973B1 (en) 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002086096A2 (en) 2001-01-23 2002-10-31 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
DE10121982B4 (en) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003219277A1 (en) 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
SI1558648T1 (en) 2002-10-17 2012-05-31 Genmab As Human monoclonal antibodies against cd20
KR101111477B1 (en) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 A conjugate comprising cholesterol linked to a therapeutic agent
DE60332957D1 (en) 2002-12-16 2010-07-22 Genentech Inc IMMUNOGLOBULIN VARIANTS AND ITS USES
AR044388A1 (en) 2003-05-20 2005-09-07 Applied Molecular Evolution CD20 UNION MOLECULES
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
EA036531B1 (en) 2003-11-05 2020-11-19 Роше Гликарт Аг Type ii anti-cd20 humanized antibody (variants), pharmaceutical composition comprising these antibody variants, and use thereof
JP5848861B2 (en) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Human monoclonal antibody against CD20
KR20160096228A (en) 2004-07-22 2016-08-12 제넨테크, 인크. Her2 antibody composition
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
DK2143795T3 (en) 2005-03-31 2011-09-19 Biomedics Inc Anti-CD20 monoclonal antibody
JP2009508467A (en) 2005-05-24 2009-03-05 アベスタゲン リミテッド Methods for generating monoclonal antibodies against CD20 for the treatment of B-cell lymphoma
CN101282993A (en) 2005-06-02 2008-10-08 阿斯利康公司 Antibodies directed to cd20 and uses thereof
JP2007036104A (en) 2005-07-29 2007-02-08 Nec Electronics Corp Semiconductor device and its manufacturing method
US20100009339A1 (en) 2006-05-18 2010-01-14 Nikolay Vladimirovich Bovin Detection method for influenza viruses
EP2035034A4 (en) 2006-06-09 2009-11-18 Univ Maryland Glycosylation engineered antibody therapy
PT2123276E (en) * 2007-02-16 2013-01-16 Toyama Chemical Co Ltd Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination
US8844722B2 (en) 2007-06-25 2014-09-30 Tom Y. Wang Medication container with Fresnel lens
US8647626B2 (en) 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
WO2009083246A1 (en) 2007-12-31 2009-07-09 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf alpha
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
CN102481364A (en) 2009-07-22 2012-05-30 安龙制药公司 Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP6057300B2 (en) 2011-01-05 2017-01-11 ナショナル タイワン ユニバーシティ Preparation of glycosphingolipids and methods of their use
US10851174B2 (en) 2011-03-03 2020-12-01 University Of Maryland, Baltimore Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof
US9328170B2 (en) 2011-05-25 2016-05-03 Merck Sharp & Dohme Corp. Method for preparing Fc containing polypeptides having improved properties
ES2841899T3 (en) 2011-07-18 2021-07-12 Inst Res Biomedicine Neutralizing antibodies to influenza A virus and their uses
US9434786B2 (en) 2012-02-10 2016-09-06 University Of Maryland, Baltimore Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
WO2013181585A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to adalimumab
WO2014070957A1 (en) 2012-10-30 2014-05-08 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
TWI599370B (en) 2013-07-26 2017-09-21 中央研究院 Antibody-mediated anti-tumor activity induced by reishi mushroom polysaccharides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123271A1 (en) * 2007-03-07 2009-11-25 Daiichi Sankyo Company, Limited Drug for treatment of influenza
WO2009029888A2 (en) * 2007-08-31 2009-03-05 Chi-Huey Wong Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THANYARAT UDOMMANEETHANAKIT ET AL: "Dynamic Behavior of Avian Influenza A Virus Neuraminidase Subtype H5N1 in Complex with Oseltamivir, Zanamivir, Peramivir, and Their Phosphonate Analogues", JOURNAL OF CHEMICAL INFORMATION AND MODELING, vol. 49, no. 10, 26 October 2009 (2009-10-26), pages 2323 - 2332, XP055008404, ISSN: 1549-9596, DOI: 10.1021/ci900277r *
VASELLA A ET AL: "Synthesis of phosphonic acid analogue of N-acetyl-2,3-didehydro-2-deo xyneuraminic acid, an inhibitor of Vibrio cholerae sialidase", HELVETICA CHIMICA ACTA 1991 CH, vol. 74, no. 2, 1991, pages 451 - 463, XP002660377, ISSN: 0018-019X *

Also Published As

Publication number Publication date
CN104777301B (en) 2018-04-20
CA2835489C (en) 2018-03-06
AU2011250970B2 (en) 2016-12-15
DK2568976T3 (en) 2016-01-11
US20130225532A1 (en) 2013-08-29
CN103068378A (en) 2013-04-24
EP2975409B1 (en) 2018-10-31
WO2011143262A2 (en) 2011-11-17
EP2568976A2 (en) 2013-03-20
CA2835489A1 (en) 2011-11-17
EP2975409A1 (en) 2016-01-20
AU2011250970A1 (en) 2013-01-10
CN104777301A (en) 2015-07-15
JP2013528160A (en) 2013-07-08
JP5947289B2 (en) 2016-07-06
KR101745386B1 (en) 2017-06-09
DK2975409T3 (en) 2018-12-17
US9403855B2 (en) 2016-08-02
US20170102387A1 (en) 2017-04-13
EP2568976B1 (en) 2015-09-30
KR101915647B1 (en) 2018-11-06
US9874562B2 (en) 2018-01-23
CN103068378B (en) 2016-07-06
KR20130085950A (en) 2013-07-30
KR20170061192A (en) 2017-06-02

Similar Documents

Publication Publication Date Title
WO2011143262A3 (en) Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
Zarubaev et al. Broad range of inhibiting action of novel camphor-based compound with anti-hemagglutinin activity against influenza viruses in vitro and in vivo
Ferraris et al. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice
PE20160127A1 (en) ACID COMPOUND (2S, 3S) -3 - ((2- (5-FLUORO-1H-PIRROLO [2,3-B] PYRIDIN-3-IL) -5-FLUOROPYRIMIDIN-4-IL) AMINO) BICICLO [2.2. 2] OCTANE-2-CARBOXYL AS AN INHIBITOR OF THE REPLICATION OF THE FLU VIRUS TO H1N1, H2N2, H3N2 or H5N1
Sakabe et al. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection
UA118010C2 (en) INFLUENCES OF INFLUENZA VIRUS REPLICATION
IN2012DN01254A (en)
GB0921730D0 (en) Method of treatment
BR112013016595A2 (en) neprilysin inhibitors
EP2201039A4 (en) Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
BRPI1014760B8 (en) preparation comprising insulin, nicotinamide and arginine
BR112014010900A2 (en) methods of preparing catalyst system
WO2010077986A3 (en) Production of influenza vaccines
BR112013001132A2 (en) process for preparation of antiviral compounds
BR112014012459A2 (en) 2h-indazoles as ep2 receptor antagonists
BR112014006559A2 (en) betulinic acid derivatives with antiviral activity
EP2269611A3 (en) EP2 and EP4 agonists as agents for the treatment of influenza A viral infection
SMT201500068B (en) New analogues of piperazine as broad-spectrum antivirals for influenza
WO2012060678A3 (en) Novel vaccines against the a/h1n1 pandemic flu virus
WO2012054907A3 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
WO2012158861A3 (en) Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
BR112014028362A2 (en) ACIDS (3R, 4R, 5S) -5-GUANIDINO-4ACETAMIDO-3- (PENTAN-3ILOXI) CYCLEEXENE-1-CARBOXYLICS SUBSTITUTED FLUOR, ITS ESTERS AND USE OF THE SAME
WO2012009373A3 (en) Compositions and assays to detect swine h1n1 influenza a virus, seasonal h1 influenza a virus and seasonal h3 influenza a virus nucleic acids
MX2014004688A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids.
GT201300003A (en) CRYSTAL FORM DELTA OF THE ARGININE SALT OF PERINDOPRILE, ITS PREPARATION PROCEDURE, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180034218.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11731548

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013510261

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20127032244

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011731548

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011250970

Country of ref document: AU

Date of ref document: 20110510

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13697794

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2835489

Country of ref document: CA